comparemela.com

Latest Breaking News On - Johnson stock exchange - Page 1 : comparemela.com

Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Thursday, July 20th to review second-quarter results. Joaquin Duato, Chairman of the Board and CEO, Joseph J. Wolk,. | June 6, 2023

Jessica mooreJosephj wolkJoaquin duatoEastern timeExecutive vice presidentChief financial officerVice presidentInvestor relationsJohnson stock exchangePress releaseOseph jnj us4781601046

Janssen Pharmaceutical - New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33 6 Months of Follow-Up with First-Line Use of RYBREVANT and Lazertinib Combination Therapy

CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a. | June 5, 2023

United statesHoon leeKiran patelSamsung medical centerClinical developmentJanssen researchYuhan corporationAmerican society of clinical oncologyJanssen biotech incSungkyunkwan university school of medicineDrug administrationJanssen pharmaceutical companiesJanssen research developmentClinical oncologyMedical centerUniversity school

Johnson & Johnson : Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 . | June 5, 2023

Noord hollandUnited statesRachel kobosSatu glaweChristie corbettEuropean commissionJanssen oncology researchAmerican society of clinical oncologyNational comprehensive cancer networkEastern cooperative oncology groupInternational myeloma working groupJanssen pharmaceutical companies of johnsonNews releasePresents longer term dataPatients achievedOverall response

Johnson & Johnson : CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study

News Release Media Contacts: Jessica Castles Smith +1 732-501-8181 Satu Glawe +49 172-294-6264 . | June 5, 2023

United statesSatu glaweBinod dhakalDivision of hematologyClinical development cellular therapy programEuropean medicines agencyJanssen biotech incCongress abstractEuropean commissionCollege of wisconsinLegend biotech united states incJanssen pharmaceutical companies of johnsonAmerican society of clinical oncologyJanssen research developmentDrug administrationNews release

Johnson & Johnson : Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 Investor Relations: Raychel. | June 5, 2023

United statesArnob banerjeeSatu glaweChristie corbettYael cohenEuropean commissionNational comprehensive cancer networkEarly development oncologyAmerican society of clinical oncologyJanssen pharmaceutical companies of johnsonJanssen research developmentAviv sourasky medical centerHematology instituteNews releasePresents first ever resultsDual bispecific combination

vimarsana © 2020. All Rights Reserved.